Showing results (71-80 of 124) with videos related to

Sort By:
Pageof 13
BMC Global and Public Health|June 4, 2024
Subclinical tuberculosis linkage to care and completion of treatment following community-based screening in rural South AfricaZolelwa Sifumba, Helgard Claassen, Stephen Olivier, et al.
Public Health Action|February 19, 2019
Targeting the third '90': introducing the viral load championH Sunpath, T J Hatlen, K K Naidu, et al.
AIDS (London, England)|March 26, 2013
Clinical and mycological predictors of cryptococcosis-associated immune reconstitution inflammatory syndromeChristina C Chang, Afton A Dorasamy, Bernadett I Gosnell, et al.
AIDS Research and Human Retroviruses|January 28, 2012
Short communication: Plasma levels of vitamin D in HIV patients initiating antiretroviral therapy do not predict immune restoration disease associated with Mycobacterium tuberculosisPatricia Price, Lewis J Haddow, Jacquita Affandi, et al.
The Journal of Infectious Diseases|June 15, 2013
Cryptococcosis-IRIS is associated with lower cryptococcus-specific IFN-γ responses before antiretroviral therapy but not higher T-cell responses during therapyChristina C Chang, Andrew Lim, Saleha Omarjee, et al.
Frontiers in Immunology|February 12, 2024
Low pre-existing endemic human coronavirus (HCoV-NL63)-specific T cell frequencies are associated with impaired SARS-CoV-2-specific T cell responses in people living with HIVTiza L Ng'uni, Vernon Musale, Thandeka Nkosi, et al.
The Journal of Infectious Diseases|May 5, 2022
Elevated Plasma Matrix Metalloproteinase 8 Associates With Sputum Culture Positivity in Pulmonary TuberculosisN F Walker, F Karim, M Y S Moosa, et al.
Frontiers in Immunology|September 28, 2020
Increased Neutrophil Count and Decreased Neutrophil CD15 Expression Correlate With TB Disease Severity and Treatment Response Irrespective of HIV Co-infectionLerato N Ndlovu, Lauren Peetluk, Sashen Moodley, et al.
The Lancet. HIV|December 4, 2025
Fixed-dose combination bictegravir-emtricitabine-tenofovir alafenamide twice-daily for treatment of HIV during rifampicin-based tuberculosis treatment (INSIGHT Study): a phase 2b, open-label, randomised non-comparative trialAnushka Naidoo, Kogieleum Naidoo, Marothi P Letsoalo, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 4, 2020
Time to embrace access programmes for medicines: lessons from the South African flucytosine access programmeAmir Shroufi, Nelesh P Govender, Graeme Meintjes, et al.
Pageof 13